NCT07920796
Thiotepa + TBI + Fludarabine + Etoposide for Allo-HSCT in Patients With R/R or High-risk Acute Leukemia
StatusEnrolling by Invitation
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
One-Year Disease-Free Survival Rate After Allogeneic Transplantation
Timeframe: From date of allo-HSCT until relapse or death from any cause, assessed up to 1year.
Secondary (13)
Complete Remission or Complete Remission With Incomplete Hematologic Recovery Rate at Day +28
Minimal Residual Disease Conversion-to-Negative Rate at Day +28
Time to Neutrophil Engraftment
Time to Platelet Engraftment
Time to Hemoglobin Recovery
Show 8 moreShow less
Overall Survival at 6, 12, and 24 Months After Allo-HSCT
Cumulative Incidence of Leukemia Relapse
Cumulative Incidence of Non-Relapse Mortality
Graft-Versus-Host Disease-Free, Relapse-Free Survival
Incidence of Acute Graft-Versus-Host Disease
Incidence of Chronic Graft-Versus-Host Disease
Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events
Incidence of Conditioning-Related Organ Toxicity
Arms and interventions
Thiotepa/TBI/Fludarabine/Etoposide Conditioning Plus Allo-HSCTExperimental
Participants receive total body irradiation, thiotepa, fludarabine, and etoposide on prespecified days before their first allogeneic hematopoietic stem cell transplantation, followed by protocol-specified assessments through 24 months after transplantation.
Drugs: Thiotepa, Fludarabine, Etoposide
Radiation: Total Body Irradiation (TBI)
Procedures: Allogeneic Hematopoietic Stem Cell Transplantation
Sites
1 site in 1 country
- Department of Hematology, Guangdong Second Provincial General HospitalGuangzhou, Guangdong, China